The Neuropathology Core (Core D) of the Johns Hopkins Alzheimer s Disease Research Center (ADRC) has three overarching goals. The first is to conduct postmortem neuropathological assessments in subjects from the ADRC and to distribute autopsy brain tissue and other biospecimens for research, the second is to support the morphological evaluation of genetically engineered mouse models by investigators associated with the ADRC, and the third is training.
The specific aims of Core D are as follows: (1) to arrange and perform autopsies on clinically well-characterized subjects enrolled through the JHMI ADRC and assist with consensus diagnoses on ADRC subjects (including the Clinic Cohort and the BLSA Cohort), (2) to accession and store optimally prepared tissues from the autopsies and to make these specimens available to investigators associated with the ADRC and at other collaborating institutions, (3) to accession and store samples of biological fluids and DNA obtained pre- and postmortem from subjects in the ADRC, (4) to facilitate APOE genotyping on participants in the ADRC, (5) to maintain a database for the integration of neuropathologic and clinical data, and the completion of the NACC Neuropathology Data Form, (6) to support the assessment of genetically engineered mouse models relevant to Alzheimer s disease (AD) and related disorders, and (7) to train basic investigators and clinical neuroscientists in the morphological and diagnostic concepts relevant to AD, to other types of dementias and neurodegenerative disorders. Despite recent advances in neuroimaging, postmortem examination remains critical to elucidate the etiology in cases of dementia and to confirm the diagnosis of AD. Furthermore, autopsy is also important to identify comorbidities, which are common in older subjects. The availability of biological fluids and postmortem tissues has become increasingly important for the research and development of biomarkers of AD. In this realm, Core D is expanding its postmortem tissue collection to include a large number of specimens from younger subjects (<50 years) suitable to examine the very early stages of AD pathology and its pathogenesis.

Public Health Relevance

NEUROPATHOLOGY CORE CORE D - PROJECT NARRATIVE The Johns Hopkins Alzheimer s Disease Research Center is an integrated program aimed at finding improved treatments for patients with Alzheimer disease (AD) and related disorders. Complimentary activities within the center include clinical and basic research studies that incorporate state-of-the art methodologies, and contribute significantly to national programs. We are dedicated to training the next generation of investigators and to reaching out to the community to improve understanding about these diseases. Specifically, Core D will conduct neuropathological autopsies and brain bank activities, distribute tissue post mortem brain tissues for research to investigators at JHU and extramurally and train young neuroscientists in the morphological and pathological aspects of AD and other neurodegenerative diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005146-36
Application #
9686550
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
2021-03-31
Budget Start
2019-04-01
Budget End
2020-03-31
Support Year
36
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Nicolas, Aude (see original citation for additional authors) (2018) Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron 97:1268-1283.e6
Bouhrara, Mustapha; Reiter, David A; Bergeron, Christopher M et al. (2018) Evidence of demyelination in mild cognitive impairment and dementia using a direct and specific magnetic resonance imaging measure of myelin content. Alzheimers Dement 14:998-1004
Xiong, Yulan; Neifert, Stewart; Karuppagounder, Senthilkumar S et al. (2018) Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice. Proc Natl Acad Sci U S A 115:1635-1640
Varma, Vijay R; Oommen, Anup M; Varma, Sudhir et al. (2018) Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. PLoS Med 15:e1002482
Wong, Dean F; Comley, Robert A; Kuwabara, Hiroto et al. (2018) Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects. J Nucl Med 59:1869-1876
Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307
Guerreiro, Rita; Ross, Owen A; Kun-Rodrigues, Celia et al. (2018) Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurol 17:64-74
Zhou, Zilu; Wang, Weixin; Wang, Li-San et al. (2018) Integrative DNA copy number detection and genotyping from sequencing and array-based platforms. Bioinformatics 34:2349-2355
Soldan, Anja; Pettigrew, Corinne; Albert, Marilyn (2018) Evaluating Cognitive Reserve Through the Prism of Preclinical Alzheimer Disease. Psychiatr Clin North Am 41:65-77
Kaur, Antarpreet; Edland, Steven D; Peavy, Guerry M (2018) The MoCA-Memory Index Score: An Efficient Alternative to Paragraph Recall for the Detection of Amnestic Mild Cognitive Impairment. Alzheimer Dis Assoc Disord 32:120-124

Showing the most recent 10 out of 830 publications